Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children

@article{Viljoen2011InfluenceOC,
  title={Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children},
  author={Michelle Viljoen and Mats O. Karlsson and Tammy M. Meyers and Hermien Gous and Collet Dandara and Malie Rheeders},
  journal={European Journal of Clinical Pharmacology},
  year={2011},
  volume={68},
  pages={339-347}
}
To investigate the influence of CYP2B6 516G>T polymorphism, as a covariate, and of interoccasion variability (IOV) on the oral clearance (CL/F) of efavirenz (EFV) in treatment-naïve black South African children over a period of 24 months post-antiretroviral therapy (ART) initiation. HIV-infected black children (n = 60, aged 3–16 years), with no prior exposure to ART, eligible to commence ART and attending an outpatient clinic were enrolled into this study. Blood samples were taken at mid-dose… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2006
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…